spacer
home > ebr > summer 2002 > singapore - a world class hub for biomedical sciences
PUBLICATIONS
European Biopharmaceutical Review

Singapore - A World Class Hub for Biomedical Sciences

Home to over 6,000 international companies with a strong base of electronics, engineering and chemical players, Singapore has also been selling itself as 'The Biopolis of Asia'. It is fast becoming a preferred location for many global biomedical companies. For a young nation with no natural resources, cosmopolitan Singapore is definitely putting itself firmly on the BioScience map. Today, Singapore has a strong contingent of leading international companies in pharmaceuticals, biotechnology, medical technology and health care services. With quality manpower, a good infrastructure, global market networks and strong intellectual property rights protection, Singapore offers an excellent operating environment for biomedical sciences companies.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Tan Hsueh Mei, Marketing Communications Department at the Singapore Economic Development Board
Tan Hsueh Mei works with the Marketing Communications Department at the Singapore Economic Development Board, promoting Singapore as an investment location.
Specifically, she oversees the marketing and communications needs of the Biomedical Sciences Group in EDB. She holds an Honours Degree in Sociology/Anthropology from the National University of Singapore.

spacer
Tan Hsueh Mei
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Pharma Services Announces Organization Updates

Philadelphia, PA – May 20, 2019 – PCI Pharma Services, a leading biopharmaceutical outsourcing services provider, is pleased to announce the following management updates to help drive the company’s future vision, strategy and growth.
More info >>

White Papers

Quality By Design

Biopharma Group

Quality by Design (QbD) is a systematic approach to development that begins with the defined objectives and emphasizes science and quality risk management in order to achieve those goals. QbD ensures that the quality of the product is built into production processes from the outset, rather than being tested after development has already commenced.
More info >>

 
Industry Events

CPhI Korea

21-23 August 2019, COEX, Seoul, South Korea

CPhI Korea provides a dynamic meeting place for a wide range of industry suppliers to engage with purchasers and decision makers from the pharmaceutical industry in Korea and the surrounding region. The exhibition showcases the whole pharma supply chain from ingredients, contracting services to machinery and biopharmaceuticals. It also hosts an extensive conference programme covering the latest trends and topics within the regional market.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement